K. Kuroi, K. Shimozuma, T. Taguchi, H. Imai, H. Yamashiro et al., Evidence-Based Risk Factors for Seroma Formation in Breast Surgery, Japanese Journal of Clinical Oncology, vol.36, issue.4, pp.197-206, 2006.
DOI : 10.1093/jjco/hyl019

R. Somers, L. Jablon, M. Kaplan, G. Sandler, and N. Rosenblatt, The Use of Closed Suction Drainage After Lumpectomy and Axillary Node Dissection for Breast Cancer A Prospective Randomized Trial, Annals of Surgery, vol.215, issue.2, pp.146-149, 1992.
DOI : 10.1097/00000658-199202000-00009

J. Classe, D. Berchery, L. Campion, R. Pioud, F. Dravet et al., Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer, British Journal of Surgery, vol.89, issue.7, pp.820-824, 2006.
DOI : 10.1002/bjs.5433

P. Taflampas, E. Sanidas, M. Christodoulakis, J. Askoxylakis, J. Melissas et al., Sealants after axillary lymph node dissection for breast cancer: good intentions but bad results, The American Journal of Surgery, vol.198, issue.1, pp.55-58, 2009.
DOI : 10.1016/j.amjsurg.2008.06.043

O. Hea, B. Ho, M. Petrek, and J. , External compression dressing versus standard dressing after axillary lymphadenectomy, Am J Surg, vol.177, pp.450-453, 1999.

D. Shamley, K. Barker, V. Simonite, and A. Beardshaw, Delayed versus immediate exercises following surgery for breast cancer: a systematic review, Breast Cancer Research and Treatment, vol.82, issue.3, pp.263-271, 2005.
DOI : 10.1007/s10549-004-4727-9

K. Porter, O. Connor, S. Rimm, E. Lopez, and M. , Electrocautery as a factor in seroma formation following mastectomy, The American Journal of Surgery, vol.176, issue.1, pp.8-11, 1998.
DOI : 10.1016/S0002-9610(98)00093-2

A. Van-bemmel, C. Van-de-velde, R. Schmitz, and G. Liefers, Prevention of seroma formation after axillary dissection in breast cancer: A systematic review, European Journal of Surgical Oncology (EJSO), vol.37, issue.10, pp.829-835, 2011.
DOI : 10.1016/j.ejso.2011.04.012

URL : https://hal.archives-ouvertes.fr/hal-00732664

M. Farthing, Octreotide in the treatment of refractory diarrhoea and intestinal fistulae., Gut, vol.35, issue.3 Suppl, pp.5-10, 1994.
DOI : 10.1136/gut.35.3_Suppl.S5

P. Carcoforo, G. Soliani, U. Maestroni, A. Donini, D. Inderbitzin et al., Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial, Journal of the American College of Surgeons, vol.196, issue.3, pp.365-374, 2003.
DOI : 10.1016/S1072-7515(02)01757-X

S. Mahmoud, K. Abdel-elah, A. Eldesoky, and S. El-awady, Octreotide Can Control Lymphorrhea after Axillary Node Dissection in Mastectomy Operations, The Breast Journal, vol.73, issue.1, pp.108-117, 2007.
DOI : 10.1016/0026-0495(90)90241-4

T. Gauthier, A. Garuchet-bigot, B. Marin, J. Mollard, O. Loum et al., Lanreotide autogel 90??mg and lymphorrhea prevention after axillary node dissection in breast cancer: A phase III double blind, randomized, placebo-controlled trial, European Journal of Surgical Oncology (EJSO), vol.38, issue.10, pp.902-911, 2012.
DOI : 10.1016/j.ejso.2012.05.009

A. Colao, S. Petersenn, J. Newell-price, J. Findling, F. Gu et al., A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease, New England Journal of Medicine, vol.366, issue.10, pp.914-938, 2012.
DOI : 10.1056/NEJMoa1105743

C. Bruns, I. Lewis, U. Briner, G. Meno-tetang, and G. Weckbecker, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile, European Journal of Endocrinology, vol.146, issue.5, pp.707-716, 2002.
DOI : 10.1530/eje.0.1460707

S. Mandrekar and D. Sargent, Randomized Phase II Trials: Time for a New Era in Clinical Trial Design, Journal of Thoracic Oncology, vol.5, issue.7, pp.932-924, 2010.
DOI : 10.1097/JTO.0b013e3181e2eadf

T. Daimon, Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials, Contemporary Clinical Trials, vol.29, issue.4, pp.507-516, 2008.
DOI : 10.1016/j.cct.2007.12.001

S. Zohar, S. Teramukai, and Y. Zhou, Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial, Contemporary Clinical Trials, vol.29, issue.4, pp.608-616, 2008.
DOI : 10.1016/j.cct.2007.11.005

A. Harris, Future medical prospects for Sandostatin, Metabolism, vol.39, issue.9, pp.180-185, 1990.
DOI : 10.1016/0026-0495(90)90241-4

A. Frati, M. Antoine, A. Rodenas, J. Gligorov, R. Rouzier et al., Somatostatin in breast cancer, Ann Biol Clin, vol.69, pp.385-391, 2011.

J. Ulibarri, Y. Sanz, C. Fuentes, A. Mancha, M. Aramendia et al., Reduction of lymphorrhagia from ruptured thoracic duct by somatostatin, The Lancet, vol.336, issue.8709, p.258, 1990.
DOI : 10.1016/0140-6736(90)91793-A

H. Schmid and P. Schoeffter, Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors, Neuroendocrinology, vol.80, issue.1, pp.47-50, 2004.
DOI : 10.1159/000080741

E. Capocasale, N. Busi, R. Valle, M. Mazzoni, L. Bignardi et al., Octreotide in the Treatment of Lymphorrhea After Renal Transplantation: A Preliminary Experience, Transplantation Proceedings, vol.38, issue.4, pp.1047-1048, 2006.
DOI : 10.1016/j.transproceed.2006.03.040

E. Wolin, K. Hu, G. Hughes, E. Bouillaud, V. Giannone et al., Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study, Cancer Chemotherapy and Pharmacology, vol.29, issue.Suppl 1, pp.387-395, 2013.
DOI : 10.1007/s00280-013-2202-1